Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on December 16, 2015. The report details a corporate action approved by the Board of Directors on November 24, 2015, regarding a forward stock split of the company's common stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Forward Stock Split: The company executed a forward stock split on a basis of 1 old share for 1.1 new shares.
- Authorized Capital: Increased to 220,000,000 shares of common stock with a par value of $0.001.
- Issued and Outstanding Shares: Increased from 39,952,984 to 43,948,286 shares.
- Trading Symbol: The stock began trading on the OTC Markets under the symbol "LXRPD" effective December 16, 2015.
- Ticker Suffix: A "D" suffix was added to the ticker symbol for 20 business days.
- CUSIP Number: Updated to 52886N307.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard regulatory disclosure of the stock split. The split was reviewed and approved by the Financial Industry Regulatory Authority (FINRA) and the Canadian Securities Exchange (CSE).
Investor Verification Checklist
- Verify the new share count of 43,948,286 outstanding shares.
- Confirm the new trading symbol "LXRPD" and the temporary "D" suffix on the OTC Markets.
- Validate the new CUSIP number 52886N307 for trading purposes.
- Review the press release (Exhibit 99.1) for additional context on the rationale for the split.